Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/54120
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAhern, M.-
dc.contributor.authorCampbell, D.-
dc.contributor.authorWeedon, H.-
dc.contributor.authorPapangelis, V.-
dc.contributor.authorSmith, M.-
dc.date.issued2008-
dc.identifier.citationAnnals of the Rheumatic Diseases, 2008; 67(9):1339-1342-
dc.identifier.issn0003-4967-
dc.identifier.issn1468-2060-
dc.identifier.urihttp://hdl.handle.net/2440/54120-
dc.description.abstractObjective: To demonstrate the efficacy of intra-articular infliximab in a patient with a persistent monarthritis who had previously had two arthroscopic synovectomies with limited success, and to determine the effect of intra-articular infliximab on synovial membrane pathology Method: Arthroscopic synovial biopsy specimens were collected before and after treatment with intra-articular infliximab. The synovial tissue was stained for a range of inflammatory cell subsets, cell adhesion molecules and cytokines using immunohistochemical techniques and quantified using digital image analysis and a semiquantitative scoring method. Results: Clinical improvement in the knee synovitis was seen after the first two intra-articular infliximab treatments, with a sustained clinical remission lasting for more than 12 months after the third treatment. Significant changes in cellular infiltration and expression of cytokines and cell adhesion molecules occurred as a result of treatment with intra-articular infliximab, with a reduction in some but not all cells in the inflammatory infiltrate, as well as a reduction in the expression of cell adhesion molecules (intercellular adhesion molecule-1 and vascular adhesion molecule-1) and production of cytokines (interleukin 1β and tumour necrosis factor α). Conclusion: Intra-articular infliximab administration is a viable treatment for a persistent monarthritis resistant to other treatment options and can successfully modulate the inflammatory milieu within the synovial membrane.-
dc.description.statementofresponsibilityM J Ahern, D G Campbell, H Weedon, V Papangelis, M D Smith-
dc.language.isoen-
dc.publisherBritish Med Journal Publ Group-
dc.source.urihttp://dx.doi.org/10.1136/ard.2008.090910-
dc.subjectSynovial Membrane-
dc.subjectHumans-
dc.subjectSpondylarthropathies-
dc.subjectSynovitis-
dc.subjectAntirheumatic Agents-
dc.subjectAntibodies, Monoclonal-
dc.subjectBiopsy-
dc.subjectInjections, Intra-Articular-
dc.subjectAdult-
dc.subjectFemale-
dc.subjectInfliximab-
dc.titleEffect of intra-articular infliximab on synovial membrane pathology in a patient with a seronegative spondyloarthropathy-
dc.typeJournal article-
dc.identifier.doi10.1136/ard.2008.090910-
pubs.publication-statusPublished-
dc.identifier.orcidCampbell, D. [0000-0002-1572-9529]-
Appears in Collections:Aurora harvest
Orthopaedics and Trauma publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.